Unveiling gut microbiota's role: Bidirectional regulation of drug transport for improved safety

被引:1
作者
Wang, Jinyi [1 ,2 ]
Zhou, Tingting [1 ,2 ]
机构
[1] Second Mil Med Univ, Sch Pharm, Dept Pharmaceut Anal, Shanghai, Peoples R China
[2] Second Mil Med Univ, Sch Pharm, Shanghai Key Lab Pharmaceut Metabolite Res, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
bidirectional regulation; drug safety; drug transport; gut microbiota; intestinal mucosal barrier; CHAIN FATTY-ACIDS; IN-VITRO; TIGHT JUNCTION; P-GLYCOPROTEIN; PARKINSONS-DISEASE; UDP-GLUCURONOSYLTRANSFERASES; MOLECULAR-MECHANISMS; ULCERATIVE-COLITIS; INTESTINAL BARRIER; ELLAGIC ACID;
D O I
10.1002/med.22077
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug safety is a paramount concern in the field of drug development, with researchers increasingly focusing on the bidirectional regulation of gut microbiota in this context. The gut microbiota plays a crucial role in maintaining drug safety. It can influence drug transport processes in the body through various mechanisms, thereby modulating their efficacy and toxicity. The main mechanisms include: (1) The gut microbiota directly interacts with drugs, altering their chemical structure to reduce toxicity and enhance efficacy, thereby impacting drug transport mechanisms, drugs can also change the structure and abundance of gut bacteria; (2) bidirectional regulation of intestinal barrier permeability by gut microbiota, promoting the absorption of nontoxic drugs and inhibiting the absorption of toxic components; (3) bidirectional regulation of the expression and activity of transport proteins by gut microbiota, selectively promoting the absorption of effective components or inhibiting the absorption of toxic components. This bidirectional regulatory role enables the gut microbiota to play a key role in maintaining drug balance in the body and reducing adverse reactions. Understanding these regulatory mechanisms sheds light on novel approaches to minimize toxic side effects, enhance drug efficacy, and ultimately improve drug safety. This review systematically examines the bidirectional regulation of gut microbiota in drug transportation from the aforementioned aspects, emphasizing their significance in ensuring drug safety. Furthermore, it offers a prospective outlook from the standpoint of enhancing therapeutic efficacy and reducing drug toxicity, underscoring the importance of further exploration in this research domain. It aims to provide more effective strategies for drug development and treatment.
引用
收藏
页码:311 / 343
页数:33
相关论文
共 241 条
[101]   Ginkgo biloba leaf extract suppresses intestinal human breast cancer resistance protein expression in mice: Correlation with gut microbiota [J].
Kim, Jeon-Kyung ;
Choi, Min Sun ;
Kim, Jae-Young ;
Yu, Jun Sang ;
Seo, Jeong In ;
Yoo, Hye Hyun ;
Kim, Dong-Hyun .
BIOMEDICINE & PHARMACOTHERAPY, 2021, 140
[102]   Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells [J].
Kitagawa, Shuji ;
Takahashi, Tomoharu ;
Nabekura, Tomohiro ;
Tachikawa, Eiichi ;
Hasegawa, Hideo .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (10) :1979-1981
[103]   The role of the intestinal microbiota in type 1 diabetes mellitus [J].
Knip, Mikael ;
Siljander, Heli .
NATURE REVIEWS ENDOCRINOLOGY, 2016, 12 (03) :154-167
[104]   Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects [J].
Koenig, Joerg ;
Mueller, Fabian ;
Fromm, Martin F. .
PHARMACOLOGICAL REVIEWS, 2013, 65 (03) :944-966
[105]   From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites [J].
Koh, Ara ;
De Vadder, Filipe ;
Kovatcheva-Datchary, Petia ;
Backhed, Fredrik .
CELL, 2016, 165 (06) :1332-1345
[106]   Chemical transformation of xenobiotics by the human gut microbiota [J].
Koppel, Nitzan ;
Rekdal, Vayu Maini ;
Balskus, Emily P. .
SCIENCE, 2017, 356 (6344) :1246-1257
[107]  
Kunes M, 2011, NEUROENDOCRINOL LETT, V32, P46
[108]   Tiny Gatekeepers: Microbial Control of Host Drug Transporters [J].
Kyaw, Than S. ;
Turnbaugh, Peter J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (03) :443-445
[109]  
Laksitorini M, 2014, THER DELIV, V5, P1143, DOI [10.4155/tde.14.67, 10.4155/TDE.14.67]
[110]   Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation [J].
Lee, John R. ;
Muthukumar, Thangamani ;
Dadhania, Darshana ;
Taur, Ying ;
Jenq, Robert R. ;
Toussaint, Nora C. ;
Ling, Lilan ;
Pamer, Eric ;
Suthanthiran, Manikkam .
PLOS ONE, 2015, 10 (03)